Experience

BriaCell Therapeutics Corp

• United States
• Biotechnology Research
• 1 - 100 Employee

• CFO

  • Feb 2016 - Present

  Toronto, Canada Area Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of… Show more Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence. Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based vaccine technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, BriaVax™, is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. BriaVax™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. In a preliminary Phase I clinical study in metastatic (i.e., Stage IV) breast cancer patients who had failed multiple treatments, BriaVax™ treatment significantly reduced the tumor size, without serious side effects. Importantly, the tumor regression was observed in other sites including the lung and even the brain -a difficult site. Impressively, the median lifespan of the patients was substantially longer than that of the comparable trials. Show less



EV Nickel Inc. (TSXV : EVNI)

• Canada
• Mining
• 1 - 100 Employee

• Director

  • Dec 2021 - Present

  Canada



Eco (Atlantic) Oil & Gas TSX-V: EOG

• Finance Director

  • Dec 2016 - Present

  Eco Atlantic Oil and Gas is an international oil and gas exploration and development company, focused on the identification, acquisition and development of upstream petroleum opportunities in politically stable and technically de-risked jurisdictions around the world. The Company is listed on the Toronto Stock Exchange (TSX-V) and has a strategic portfolio of offshore projects in Guyana (South America) and Namibia (Africa). In partnership with Tullow Oil, Eco Atlantic holds a 40%… Show more Eco Atlantic Oil and Gas is an international oil and gas exploration and development company, focused on the identification, acquisition and development of upstream petroleum opportunities in politically stable and technically de-risked jurisdictions around the world. The Company is listed on the Toronto Stock Exchange (TSX-V) and has a strategic portfolio of offshore projects in Guyana (South America) and Namibia (Africa). In partnership with Tullow Oil, Eco Atlantic holds a 40% working interest in the 1800 km2 Orinduik offshore block in the shallow water of the prospective Guyana-Suriname basin. Notably, the licence area is adjacent and updip to ExxonMobil’s world class Liza discoveries where recoverable resources could be c.1.4 Billion barrels and field development planning has begun in earnest. In offshore Namibia, Eco Atlantic operates and is the major interest owner of four prospective licence blocks in the Walvis Basin; Sharon, Cooper, Guy and Tamar. It is estimated that 25 billion barrels of prospective resources could be held within this licence area. The Walvis Basin is a proven petroleum system and Eco Atlantic is working in partnership with Tullow Oil, NAMCOR and AziNam on projects in the region. Eco Atlantic comprises a qualified and experienced management team, whose skills are utilised to operate the offshore licences. When a licence is acquired, Eco looks to bring on board a reputable and globally recognised oil and gas partner to assist with the development and operating of the licence block. In addition, Eco Atlantic’s Board and Management team fully understand the assets and the countries in which it operates, which leads to the development of successful relations with local governments and with other oil and gas companies operating in the region. Show less



Vaxil Bio Ltd.

• Israel
• Biotechnology Research
• 1 - 100 Employee

• CFO

  • Mar 2016 - Present

  Vaxil's primary immunotherapy product is the ImMucin signal peptide cancer vaccine, which demonstrated very encouraging results in a Phase I/II study on 15 Multiple Myeloma patients. All the patients treated displayed a specific and robust immune response and 11 out of the 15 patients also derived clinical benefit. A small group of patients were followed post treatment with some patients continuing to derive clinical benefit for periods of several years post-treatment. Vaxil's ImMucin has also… Show more Vaxil's primary immunotherapy product is the ImMucin signal peptide cancer vaccine, which demonstrated very encouraging results in a Phase I/II study on 15 Multiple Myeloma patients. All the patients treated displayed a specific and robust immune response and 11 out of the 15 patients also derived clinical benefit. A small group of patients were followed post treatment with some patients continuing to derive clinical benefit for periods of several years post-treatment. Vaxil's ImMucin has also received Orphan Drug Status from both the FDA (June 2015) and EMA (March 2015). Vaxil is currently in the process of planning and preparing its submissions to the regulator to receive approval for a larger Phase II study with ImMucin in Multiple Myeloma patients. More recently, Vaxil signed a preliminary agreement to collaborate with the Mayo Clinic which would see ImMucin tested as a combination therapy together with immunotherapeutic products and technology under development by the Mayo Clinic. Show less


Adira Energy Ltd
• CFO

  • Jul 2010 - Mar 2018


Labstyle Innovations- Dario

• CFO

  • Nov 2013 - Jan 2015

  Israel



Profimex

• Israel
• Real Estate
• 1 - 100 Employee

• CFO

  • Jan 2010 - Aug 2010

  Profimex is a global real estate investment firm providing institutional investors, public companies, private companies and High Net Worth Individuals, access to cross border, diversified real estate investments. Amongst Profimex's institutional investors are insurance companies, pension funds, provident funds and banks. Profimex specializes in co-investments with global partners who are established leading real estate investment companies with proven track records.



KCPS & Company

• Director of Finance

  • Nov 2007 - Jan 2010

  kcps.com


selfemployed
• Translation and Localization
• 700 & Above Employee
• Financial Consultant

  • Jul 2003 - Nov 2007

Ernst & Young
• China
• Accounting
• 700 & Above Employee
• Senior Manager

  • 2002 - 2003

Arthur Andersen
• Denmark
• Truck Transportation
• 1 - 100 Employee
• Manager

  • Jan 1995 - 2002